XENE - ゼノン・ファ―マシュ―ティカルズ (Xenon Pharmaceuticals Inc.) ゼノン・ファ―マシュ―ティカルズ

 XENEのチャート


 XENEの企業情報

symbol XENE
会社名 Xenon Pharmaceuticals Inc (ゼノン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera TV-45070 GDC-0310 XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101 is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.   ゼノン・ファ―マシュ―ティカルズはカナダのバイオ医薬品会社。同社は希少疾患に対する医薬品の開発に従事する。リポタンパクリバ―ゼ欠損症、帯状疱疹後神経痛、ドラベ症候群(難治性てんかん)、炎症性痛、神経障害痛などイオンチャネルの変異による疾患向け治療薬の臨床段階の治験を行う。本社はブリティッシュコロンビア州バ―ナビ―。   Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
本社所在地 200-3650 Gilmore Way Burnaby British Columbia V5G 4W8 CAN
代表者氏名 Michael M. Tarnow Michael M. Tarnow
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 604-484-3300
設立年月日 35370
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 81人
url www.xenon-pharma.com
nasdaq_url https://www.nasdaq.com/symbol/xene
adr_tso
EBITDA EBITDA(百万ドル) -31.48200
終値(lastsale) 10.8901
時価総額(marketcap) 223921027.3989
時価総額 時価総額(百万ドル) 262.84410
売上高 売上高(百万ドル) 0.28000
企業価値(EV) 企業価値(EV)(百万ドル) 233.12010
当期純利益 当期純利益(百万ドル) -26.36700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Xenon Pharmaceuticals Inc revenues decreased from $31K to $0K. Net loss applicable to common stockholders decreased 29% to $10.6M. Revenues reflect Collaboration revenue decrease from $30K to $0K. Lower net loss reflects Research and development decrease of 9% to $11M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.83 to -$0.72.

 XENEのテクニカル分析


 XENEのニュース

   Xenon Pharmaceuticals Provides Corporate Update Following  2021/06/25 01:17:22 Intrado Digital Media
Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders GlobeNewswire
   Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders  2021/06/03 00:00:00 BioSpace
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders held on June 3, 2021.
   Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference  2021/05/31 00:00:00 BioSpace
Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that members of its executive management team will participate in the following investor conference
   Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2021 Results - Earnings Call Transcript  2021/05/12 03:14:05 Seeking Alpha
   Xenon Pharmaceuticals: Q1 Earnings Snapshot  2021/05/11 20:26:38 CityNews Vancouver
BURNABY, British Columbia (AP) _ Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $15.8 million in its first quarter. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 42 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research []
   BidaskClub Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Strong Sell  2020/10/24 07:18:45 Zolmax News
Xenon Pharmaceuticals (NASDAQ:XENE) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday, BidAskClub reports. Other research analysts have also issued research reports about the company. SVB Leerink began coverage on Xenon Pharmaceuticals in a research report on Friday, […]
   Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $10.33 Million  2020/10/23 22:46:45 Daily Political
Analysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report sales of $10.33 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.20 million and the highest estimate coming in at $22.44 million. Xenon Pharmaceuticals posted sales of $3.50 […]
   Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 20:01:00 GlobeNewswire
XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. …
   Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/30 20:01:00 GlobeNewswire
BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today…
   BidaskClub Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Strong Sell  2020/10/24 07:18:45 Zolmax News
Xenon Pharmaceuticals (NASDAQ:XENE) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday, BidAskClub reports. Other research analysts have also issued research reports about the company. SVB Leerink began coverage on Xenon Pharmaceuticals in a research report on Friday, […]
   Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $10.33 Million  2020/10/23 22:46:45 Daily Political
Analysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report sales of $10.33 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.20 million and the highest estimate coming in at $22.44 million. Xenon Pharmaceuticals posted sales of $3.50 […]
   Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 20:01:00 GlobeNewswire
XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. …
   Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/30 20:01:00 GlobeNewswire
BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today…
   Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates  2020/05/21 21:15:03 Zacks Investment Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゼノン・ファ―マシュ―ティカルズ XENE Xenon Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)